Unmasking Arrhythmogenic Hubs of Reentry Driving Persistent Atrial Fibrillation for Patient-Specific Treatment.
Brian J. Hansen,Jichao Zhao,Katelynn M. Helfrich,Ning Li,Alexander Iancau,Alexander M. Zolotarev,Stanislav O. Zakharkin,Anuradha Kalyanasundaram,Megan Subr,Nawshin Dastagir,Roshan Sharma,Esthela J. Artiga,Nicholas Salgia,Mustafa M. Houmsse,Omar Kahaly,Paul M. L. Janssen,Peter J. Mohler,Nahush A. Mokadam,Bryan A. Whitson,Muhammad R. Afzal,Orlando P. Simonetti,John D. Hummel,Vadim V. Fedorov
DOI: https://doi.org/10.1161/jaha.120.017789
IF: 6.106
2020-10-05
Journal of the American Heart Association
Abstract:Background Atrial fibrillation (AF) driver mechanisms are obscured to clinical multielectrode mapping approaches that provide partial, surface‐only visualization of unstable 3‐dimensional atrial conduction. We hypothesized that transient modulation of refractoriness by pharmacologic challenge during multielectrode mapping improves visualization of hidden paths of reentrant AF drivers for targeted ablation. Methods and Results Pharmacologic challenge with adenosine was tested in ex vivo human hearts with a history of AF and cardiac diseases by multielectrode and high‐resolution subsurface near‐infrared optical mapping, integrated with 3‐dimensional structural imaging and heart‐specific computational simulations. Adenosine challenge was also studied on acutely terminated AF drivers in 10 patients with persistent AF. Ex vivo, adenosine stabilized reentrant driver paths within arrhythmogenic fibrotic hubs and improved visualization of reentrant paths, previously seen as focal or unstable breakthrough activation pattern, for targeted AF ablation. Computational simulations suggested that shortening of atrial refractoriness by adenosine may (1) improve driver stability by annihilating spatially unstable functional blocks and tightening reentrant circuits around fibrotic substrates, thus unmasking the common reentrant path; and (2) destabilize already stable reentrant drivers along fibrotic substrates by accelerating competing fibrillatory wavelets or secondary drivers. In patients with persistent AF, adenosine challenge unmasked hidden common reentry paths (9/15 AF drivers, 41±26% to 68±25% visualization), but worsened visualization of previously visible reentry paths (6/15, 74±14% to 34±12%). AF driver ablation led to acute termination of AF. Conclusions Our ex vivo to in vivo human translational study suggests that transiently altering atrial refractoriness can stabilize reentrant paths and unmask arrhythmogenic hubs to guide targeted AF driver ablation treatment. Nonstandard Abbreviations and Acronyms 3D 3‐ dimensional AFCL atrial fibrillation cycle length CE‐MRI contrast‐enhanced magnetic resonance imaging DE‐CMR delayed enhancement cardiac magnetic resonance MEM multielectrode mapping NIOM near‐infrared optical mapping PVI pulmonary vein isolation Clinical Perspective What Is New? This study demonstrates that persistent atrial fibrillation can be maintained by reentrant drivers within a fibrotic arrhythmogenic hub composed of multiple pathways, allowing beat‐to‐beat variability to obscure activation mapping. What Are the Clinical Implications Adenosine challenge can be used in patients with persistent atrial fibrillation to transiently stabilize reentrant drivers, unmask associated arrhythmogenic hubs and improve driver identification via multielectrode mapping. Structural and electrophysiological features of arrhythmogenic hubs are potential targets for efficient driver ablation in patients with persistent atrial fibrillation. Atrial fibrillation (AF) continues to pose a serious and worsening health burden. 1 Conventional cardiac ablation treatment of persistent AF suffers from low success rates, partly because of unresolved AF mechanisms. 1 Recent clinical studies suggest that ablation of persistent AF could be improved by targeting spatially stable, extrapulmonary sources of repetitive, rotational activity (reentrant AF drivers) identified by multielectrode mapping (MEM). 2 , 3 , 4 , 5 Typically, AF driver mechanisms are identified by their activation patterns and stability over time. Current clinical mapping, however, is restricted to surface‐onl -Abstract Truncated-
cardiac & cardiovascular systems